BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates
BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,
How this was made
The 30-second read
Why it matters
The raised guidance signals continued growth momentum, likely attracting institutional buying and supporting a higher valuation multiple.
Market read
The earnings beat and guidance raise are material for biotech investors and may influence sector sentiment.
What to watch
Potential risks include regulatory scrutiny of new products and execution of upcoming pipeline milestones.
Total revenue rose 34% to $1.9 billion in the third quarter, led by 34% global BRUKINSA growth, while BeOne raised its full-year 2026 revenue and operating-income guidance.
Third-quarter revenue, operating income, net income, diluted ADS earnings and free cash flow all increased materially from the prior-year period, gross margin expanded, and the company raised full-year revenue, GAAP operating-income and non-GAAP operating-income guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 net product revenuesGAAP | $1.86B | – | 33 % |
| Q3 2026 other revenueGAAP | $34.76M | – | 101 % |
| Q3 2026 total revenueGAAP | $1.89B | – | 34 % |
| Nine months ended September 30, 2026 net product revenuesGAAP | $5.02B | – | 32 % |
| Nine months ended September 30, 2026 other revenueGAAP | $86.14M | – | 120 % |
| Nine months ended September 30, 2026 total revenueGAAP | $5.11B | – | 33 % |
| Q3 2026 gross margin as a percentage of global product salesGAAP | 88% | – | – |
| Q3 2026 adjusted gross margin as a percentage of product salesnon-GAAP | 90% | – | – |
| Q3 2026 gross profitGAAP | $1.67B | – | – |
| Q3 2026 research and development expenseGAAP | $660.8M | – | 26 % |
| Q3 2026 adjusted research and development expensenon-GAAP | $586.2M | – | 31 % |
| Q3 2026 selling, general and administrative expenseGAAP | $593.5M | – | 12 % |
| Q3 2026 adjusted selling, general and administrative expensenon-GAAP | $503.7M | – | 16 % |
| Q3 2026 total operating expensesGAAP | $1.25B | – | 19 % |
| Q3 2026 adjusted operating expensesnon-GAAP | $1.09B | – | 24 % |
| Nine months ended September 30, 2026 research and development expenseGAAP | $1.81B | – | 19 % |
| Nine months ended September 30, 2026 adjusted research and development expensenon-GAAP | $1.59B | – | 21 % |
| Nine months ended September 30, 2026 selling, general and administrative expenseGAAP | $1.74B | – | 14 % |
| Nine months ended September 30, 2026 adjusted selling, general and administrative expensenon-GAAP | $1.48B | – | 16 % |
| Nine months ended September 30, 2026 total operating expensesGAAP | $3.56B | – | 16 % |
| Nine months ended September 30, 2026 adjusted operating expensesnon-GAAP | $3.06B | – | 19 % |
| Q3 2026 income from operationsGAAP | $418.7M | – | 157 % |
| Q3 2026 adjusted income from operationsnon-GAAP | $612.2M | – | 79 % |
| Nine months ended September 30, 2026 income from operationsGAAP | $993.6M | – | 279 % |
| Nine months ended September 30, 2026 adjusted income from operationsnon-GAAP | $1.53B | – | 102 % |
| Q3 2026 net incomeGAAP | $384.7M | – | 208 % |
| Q3 2026 adjusted net incomenon-GAAP | $538.7M | – | 77 % |
| Nine months ended September 30, 2026 net incomeGAAP | $849.1M | – | 285 % |
| Nine months ended September 30, 2026 adjusted net incomenon-GAAP | $1.36B | – | 96 % |
| Q3 2026 basic earnings per ADSGAAP | $ 3.38 | – | 199 % |
| Q3 2026 adjusted basic earnings per ADSnon-GAAP | $ 4.74 | – | 72 % |
| Q3 2026 diluted earnings per ADSGAAP | $ 3.28 | – | 201 % |
| Q3 2026 adjusted diluted earnings per ADSnon-GAAP | $ 4.59 | – | 73 % |
| Nine months ended September 30, 2026 diluted earnings per ADSGAAP | $ 7.30 | – | 272 % |
| Nine months ended September 30, 2026 adjusted diluted earnings per ADSnon-GAAP | $ 11.68 | – | 90 % |
| Q3 2026 net cash provided by operating activitiesGAAP | $508.7M | – | – |
| Q3 2026 free cash flownon-GAAP | $473.5M | – | 34 % |
| Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP | $1.17B | – | – |
| Nine months ended September 30, 2026 free cash flownon-GAAP | $1.07B | – | 90 % |
| Cash, cash equivalents and restricted cash as of September 30, 2026GAAP | $5.87B | – | – |
| Debt as of September 30, 2026GAAP | $1.07B | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| BRUKINSA (zanubrutinib) global salesFoundational BTK inhibitor; the company cited its role in rapid global growth and leadership in hematology. | $1.4B | – | 34% |
| BRUKINSA (zanubrutinib) U.S. salesU.S. BRUKINSA sales growth. | $1B | – | 36% |
| TEVIMBRA (tislelizumab) global salesGlobal sales growth; TEVIMBRA received Japan regulatory approval for first-line nasopharyngeal cancer. | $243M | – | 28% |
| Amgen in-licensed products global salesGlobal sales growth. | $167M | – | 26% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full Year 2026 outlook
- Revenue$6.9B - $7.0B
- Gross marginHigh-80% range
- Operating expenses$4.9B - $5.0B
- NoteGAAP operating income: $1.2B - $1.3B
- NoteNon-GAAP operating income: $1.9B - $2.0B
- NoteOther income (expense): Estimated range of $25 million to $50 million in expense, includes interest amortization from the Royalty Pharma arrangement.
- NoteEarnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized.
- NoteDiluted ADS outstanding: approximately 118 million.
- NoteAssumes November 1, 2026 foreign exchange rates.
- NoteGAAP operating expenses and operating income guidance does not assume any potential new, material business development activity or unusual/non-recurring items.
What drove it
- Total revenue growth was led by global BRUKINSA sales growth.
- GAAP gross margin increased due to a proportionally higher sales mix of global BRUKINSA and productivity improvements that lowered costs for BRUKINSA and TEVIMBRA.
- R&D expense increased as early clinical programs advanced into late stage and preclinical programs moved into the clinic.
- SG&A expense increased with continued investment to support commercial growth.
- GAAP net income increased primarily because of revenue growth and improved operating leverage.
Concerns
- Gross margin included a non-cash intangible asset impairment charge of $22 million associated with the decision to discontinue promotion of POBEVCY.
- Interest expense was $ 42,407 in Q3 2026, compared to $ 16,364 in Q3 2025.
- The company expects other income (expense) of $25 million to $50 million in expense for full-year 2026, including interest amortization from the Royalty Pharma arrangement.
- Full-year guidance does not assume potential new, material business development activity or unusual/non-recurring items.
- The company expects a reversal of certain valuation allowances to occur in the fourth quarter of 2026, with the magnitude still under evaluation.
What to watch
- Q4 2026 regulatory submission in Japan for BRUKINSA in first-line mantle cell lymphoma.
- Q4 2026 initiation of GroundBBreaker-301 and GroundBBreaker-201 studies for BGB-B2033 in hepatocellular carcinoma.
- First-half 2027 China regulatory actions for TEVIMBRA and ZIIHERA regimens in first-line HER2-positive gastroesophageal adenocarcinoma.
- Mid-2027 potential Phase 2 submission for tacabrutideg in relapsed/refractory chronic lymphocytic leukemia.
- The expected fourth-quarter 2026 valuation-allowance reversal and related material tax benefit.
Balance sheet and cash flow
- Cash, cash equivalents and restricted cash as of September 30, 2026: $ 5,866,314, compared to $ 4,609,647 as of December 31, 2025.
- Debt as of September 30, 2026: $ 1,074,081, compared to $ 1,019,206 as of December 31, 2025.
- Total assets as of September 30, 2026: $ 9,875,925, compared to $ 8,188,573 as of December 31, 2025.
- Total liabilities as of September 30, 2026: $ 4,055,531, compared to $ 3,827,379 as of December 31, 2025.
- Total equity as of September 30, 2026: $ 5,820,394, compared to $ 4,361,194 as of December 31, 2025.
- Q3 2026 purchases of property, plant and equipment: $ 35,175, compared to $ 48,084 in Q3 2025.
- Nine months ended September 30, 2026 purchases of property, plant and equipment: $ 103,440, compared to $ 148,317 in the prior-year period.
Analysis
BeOne reported a strong third quarter of 2026. Total revenue was $ 1,889,815, up 34 % from $ 1,412,284 in the prior-year period, while net product revenues increased 33 % to $ 1,855,057. BRUKINSA global sales were $1.4 billion and increased 34%, with U.S. sales of $1.0 billion increasing 36%. TEVIMBRA global sales were $243 million, up 28%, and Amgen in-licensed products generated $167 million, up 26%.
Profitability expanded faster than revenue on a GAAP basis. GAAP income from operations increased 157 % to $ 418,675 and GAAP net income increased 208 % to $ 384,706. GAAP gross margin as a percentage of global product sales rose to 88% from 86%, supported by a greater BRUKINSA sales mix and productivity improvements for BRUKINSA and TEVIMBRA. The result included a $22 million non-cash intangible asset impairment charge associated with discontinuing promotion of POBEVCY. Adjusted gross margin was 90%, compared with 86% in the prior-year period.
Investment continued alongside operating leverage. Q3 GAAP R&D expense rose 26 % to $ 660,784 as clinical programs advanced, while GAAP SG&A expense rose 12 % to $ 593,460 to support commercial growth. Total GAAP operating expenses increased 19 %, below total-revenue growth. Diluted GAAP earnings per ADS were $ 3.28, compared with $ 1.09, and adjusted diluted earnings per ADS were $ 4.59, compared with $ 2.65.
Cash generation was also higher. Q3 net cash provided by operating activities was $ 508,707, compared with $ 402,553, and free cash flow was $ 473,532, compared with $ 354,469. Cash, cash equivalents and restricted cash were $ 5,866,314 as of September 30, 2026, while debt was $ 1,074,081. The release did not report dividends or share repurchases.
Management raised full-year 2026 total-revenue guidance to $6.9B - $7.0B from $6.6B - $6.8B. It also raised GAAP operating-income guidance to $1.2B - $1.3B from $1.0B - $1.1B and non-GAAP operating-income guidance to $1.9B - $2.0B from $1.7B - $1.8B. GAAP operating-expense guidance is $4.9B - $5.0B, versus prior guidance of $4.8B - $5.0B, and gross-margin guidance remains in the high-80% range. The company also identified potential fourth-quarter 2026 reversal of valuation allowances as a prospective material tax benefit.
Management, verbatim
Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported financial metrics were not provided.
- Capital returns, including share repurchases and dividends, were not reported.
- A numerical full-year 2026 tax-rate outlook was not reported.
- A GAAP operating cash flow or free cash flow margin was not reported.
- Actual full-year 2026 results are not reported because the fiscal year is not complete.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BeOne Medicines reported Q3 2026 results, highlighting $1.9 billion quarterly revenue and a 34% YoY increase for its BTK inhibitor BRUKINSA.
Ticker impact
BeOne Medicines raised 2026 total revenue guidance to $6.9‑$7.0 billion and GAAP operating income to $1.2‑$1.3 billion in its Q3 2026 results.
likely upward pressure as investors price in higher revenue and earnings expectations
The company disclosed materially higher full‑year guidance alongside strong quarterly earnings, which typically drives buying interest.
Market effects
Boosts outlook for oncology and biotech sector as a leading BTK inhibitor shows strong sales momentum.
Positive for US‑listed biotech stocks and may lift broader health‑care indices.
Reinforces confidence in global oncology drug pipelines, especially for BTK and BCL2 inhibitors.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyBeOne Medicines Ltd.
Global oncology company listed on NASDAQ (ONC).
